Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Thorsten Graef"'
Autor:
Vincent Ribrag, Won Seog Kim, Reda Bouabdallah, Soon Thye Lim, Bertrand Coiffier, Arpad Illes, Bernard Lemieux, Martin J. S. Dyer, Fritz Offner, Zakia Felloussi, Ioana Kloos, Ying Luan, Remus Vezan, Thorsten Graef, Franck Morschhauser
Publikováno v:
Haematologica, Vol 102, Iss 5 (2017)
Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histon
Externí odkaz:
https://doaj.org/article/60433ef50a7d46828fefcd21b05bbe64
Autor:
Nancy L. Bartlett, Thorsten Graef, Sharon Horton, Ying Luan, Jeanne Yue, Chitra Mani, Mint Sirisawad, Julian Sprague, Robert Langdon, Leo I. Gordon, Wael Harb, Julie M. Vose, Sriram Balasubramanian, Andrew M. Evens
SUPPLEMENTAL APPENDIX Supplemental Table 1. Phase I Abexinostat Dosing Schedule and Dose Levels. Supplemental Table 2. Dose-Limiting Toxicities. Supplemental Table 3. Adverse Events of {greater than or equal to} Grade 3 (Phase I All-treated Populatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::148edf227246deea9169ee087b5d95a9
https://doi.org/10.1158/1078-0432.22457025
https://doi.org/10.1158/1078-0432.22457025
Autor:
Nancy L. Bartlett, Thorsten Graef, Sharon Horton, Ying Luan, Jeanne Yue, Chitra Mani, Mint Sirisawad, Julian Sprague, Robert Langdon, Leo I. Gordon, Wael Harb, Julie M. Vose, Sriram Balasubramanian, Andrew M. Evens
Purpose: Additional targeted therapeutics are needed for the treatment of lymphoma. Abexinostat is an oral pan-histone deacetylase inhibitor (HDACi) displaying potent activity in preclinical models. We conducted a multicenter phase I/II study (N = 55
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::895565694d4d91a920bec69459c9ec4d
https://doi.org/10.1158/1078-0432.c.6523488.v1
https://doi.org/10.1158/1078-0432.c.6523488.v1
Autor:
Alessandra Tedeschi, Paula Cramer, Anthony R. Mato, Marie Sarah Dilhuydy, Thorsten Graef, John C. Byrd, Stephen Chang, Jan A. Burger, Tony Lin, Paul M. Barr
Publikováno v:
British Journal of Haematology. 186:175-180
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf368f038820d9db3a2f4c2a17ae2afa
https://doi.org/10.1111/bjh.15784
https://doi.org/10.1111/bjh.15784
Autor:
Jason C. Chandler, Michael H. Veeder, Alain C. Mita, Thomas J. George, David S. Hong, Drew W. Rasco, Shanhong Guan, Selda Samakoglu, Martin Gutierrez, Isaiah W. Dimery, Pamela N. Munster, Ani Sarkis Balmanoukian, Jason J. Luke, Thorsten Graef, Erkut Borazanci, Heather A. Wakelee, Jordan Berlin
Publikováno v:
Oncology. 97:102-111
Background: Ibrutinib, a first-in-class, once-daily inhibitor of Bruton’s tyrosine kinase, is approved in the United States for the treatment of various B-cell malignancies. Preclinical data suggest synergistic antitumor activity of ibrutinib with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::693a9d6aa358ab471837d0efbad8a2c7
https://doi.org/10.1159/000500571
https://doi.org/10.1159/000500571
Autor:
Tai-Sheng Wu, Hao-Kang Li, Ching-Wen Hsiao, Yi-Hung Ou, Zih-Fei Cheng, Hsiu-Ping Yang, Sen-Han Yang, Chia-Yun Lee, Yan-Liang Lin, Thorsten Graef, Sai-Wen Tang, Sonny Hsiao
Publikováno v:
Cancer Research. 82:5573-5573
Introduction Autologous CAR-T has improved clinical outcomes in hematological malignancies; however need remains to improve the toxicities, relapse rates, treatment delays and costs. ACE1831 is a novel, off-the-shelf Antibody Conjugated Effector cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83f3c4a64120fed34dd73c281df25f94
https://doi.org/10.1158/1538-7445.am2022-5573
https://doi.org/10.1158/1538-7445.am2022-5573
Autor:
Javid Moslehi, Simon Rule, Martin Dreyling, Susan O'Brien, Amulya Bista, Rudolph Valentino, Stephen Chang, Steven Coutre, Michelle Mahler, Thorsten Graef, Huiying Yang, Marie Sarah Dilhuydy, Rama Vempati, Paolo Ghia, Paula Cramer, John C. Byrd, Michael S. Ewer, Florence Cymbalista, Steven P. Treon, Jennifer R. Brown, Graeme Fraser, Emily Y. Liu, Ulrich Jaeger, Jan A. Burger, Vijay Reddy, Tait D. Shanafelt, Lisa Boornazian
Publikováno v:
British Journal of Haematology
Summary Ibrutinib, a Bruton tyrosine kinase inhibitor, is approved for treatment of various B‐cell malignancies. In ibrutinib clinical studies, low‐grade haemorrhage was common, whereas major haemorrhage (MH) was infrequent. We analysed the incid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcd1cc53a072c32988be1ceeff84f2db
http://europepmc.org/articles/PMC6587776
http://europepmc.org/articles/PMC6587776
Autor:
Xavier Leleu, Roman Hájek, Shalal Sadullah, Mei Cheng, Efstathios Kastritis, Alessandra Tedeschi, Christian Buske, Monique C. Minnema, Ramón García-Sanz, Lukasz Bolkun, Wolfgang Willenbacher, Thorsten Graef, Elizabeth Bilotti, Meletios A. Dimopoulos
Publikováno v:
The Lancet Haematology, 5(7), e299. Lancet Publishing Group
Summary Background Treatment options for Waldenstrom's macroglobulinaemia are heterogeneous, and no well established treatment standards exist. Although guidelines from the Eighth International Workshop on Waldenstrom's Macroglobulinemia were publish
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5815e2201e2ba2447bef2a77da0e2f36
https://doi.org/10.1016/s2352-3026(18)30087-5
https://doi.org/10.1016/s2352-3026(18)30087-5
Autor:
Saad Z. Usmani, Zeena Salman, Lipo Chang, Robert F. Cornell, Beata Holkova, Yihua Lee, Larry D. Anderson, Elizabeth Bilotti, Chatchada Karanes, Cristina Gasparetto, Yvonne Pak, Ruben Niesvizky, Jason Valent, Sarah Larson, Thorsten Graef, Jeffrey Matous, Saurabh Chhabra, Ajai Chari, Matthew A. Lunning
Publikováno v:
Leukemia & Lymphoma. 59:2588-2594
This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent). Of 43 patients enro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dbeadcdb9a4f2367e52963a73c894cf
https://doi.org/10.1080/10428194.2018.1443337
https://doi.org/10.1080/10428194.2018.1443337
Autor:
Paolo Andrea Zucali, Jeff Hsu, Jean-Charles Soria, Ying Luan, Sofia Rivera, Jean Menard, Eric Deutsch, Thorsten Graef, Ioana Kloos, Remus Vezan, Elizabeth Cohen-Jonathan Moyal, Emily Liu, Vanesa Gregorc
Publikováno v:
Oncotarget
// Eric Deutsch 1, 2, 3 , Elizabeth Cohen-Jonathan Moyal 4 , Vanesa Gregorc 5 , Paolo Andrea Zucali 6 , Jean Menard 7 , Jean-Charles Soria 8 , Ioana Kloos 9 , Jeff Hsu 10 , Ying Luan 10 , Emily Liu 10 , Remus Vezan 10 , Thorsten Graef 10 , Sofia Rive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1f1b2b38afaaa42259dda6fafbbf46f
https://doi.org/10.18632/oncotarget.14147
https://doi.org/10.18632/oncotarget.14147